Nicholas Latimer

Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data

Nicholas Latimer · Medical Decision Making · 2013 · 535 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial

Rebecca Palmer, Munyaradzi Dimairo, Cindy Cooper et al. · The Lancet Neurology · 2019 · 196 citations · Full text

Health Professions, Neurology, Speech-language Pathology +17

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study

James P. Morden, Paul C. Lambert, Nicholas Latimer et al. · BMC Medical Research Methodology · 2011 · 117 citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +15

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis

Nicholas Latimer, Joanne Lord, Robert Grant et al. · BMJ · 2009 · 114 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context

Nicholas Latimer, Keith R. Abrams, Paul C. Lambert et al. · Medical Decision Making · 2014 · 103 citations

Medicine, Biostatistics, Oncology +16